What is the diagnosis and treatment for oral cancer (Squamous Cell Carcinoma) of the tongue?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Tongue cancer treatment should be discussed in a multidisciplinary team (MDT) and patients should be treated at high-volume facilities to optimize outcomes. The treatment strategy for tongue cancer, a type of squamous cell carcinoma of the oral cavity, should be based on patient- and treatment-related factors, such as side effects and complications, as conservative surgery and radiation therapy (RT) may often provide similar locoregional control 1.

Treatment Options

  • Early disease should be treated as much as possible with a single-modality treatment, such as surgery or RT alone 1.
  • For locally advanced disease, standard options include surgery plus adjuvant (chemo)radiation therapy (CRT) or primary concomitant CRT 1.
  • Primary surgical treatment followed by RT or CRT is the preferred treatment for T3/T4 oral cavity cancers 1.
  • Concomitant CRT increases locoregional control and overall survival (OS) compared with RT alone, and a hypoxic radiosensitiser can also increase locoregional control and disease-free survival compared with RT alone 1.

Chemotherapy

  • The standard of care for chemotherapy (ChT) is cisplatin at a dose of 100 mg/m² given on days 1,22, and 43 of concomitant RT (70 Gy) 1.
  • In patients unfit for cisplatin, carboplatin combined with 5-FU or cetuximab concomitant to RT, as well as hyperfractionated or accelerated RT without ChT, are treatment alternatives 1.
  • Pembrolizumab in combination with platinum/5-FU and pembrolizumab monotherapy are approved regimens for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) expressing PD-L1 (CPS 1) 1.

Postoperative Care

  • Postoperative RT is recommended for patients with pT3/T4 tumors, resection margins with macroscopic (R2) or microscopic (R1) residual disease, perineural infiltration, lymphatic infiltration, >1 invaded lymph node, and the presence of extracapsular infiltration 1.
  • Postoperative CRT is recommended for patients with an R1 resection and extracapsular rupture 1.
  • Postoperative RT or CRT should start within 6-7 weeks of surgery 1.

From the Research

Treatment Options for Tongue Cancer

  • There are various treatment options for tongue cancer, including surgery, radiation therapy, and chemotherapy 2, 3, 4, 5, 6.
  • The choice of treatment depends on the stage and location of the cancer, as well as the patient's overall health.

Chemotherapy and Radiation Therapy

  • Chemotherapy and radiation therapy can be used together to treat tongue cancer, with studies showing promising results 2, 3, 4, 5.
  • One study found that concurrent platinum-based chemotherapy and simultaneous modulated accelerated radiation therapy resulted in excellent survival rates and organ function for patients with base of tongue cancer 4.
  • Another study found that arterial chemoradiotherapy using cisplatin with sodium thiosulfate resulted in excellent therapeutic results for locally advanced tongue cancer 5.

Surgery and Induction Chemotherapy

  • Surgery can be used to treat tongue cancer, either alone or in combination with induction chemotherapy and risk-adapted adjuvant therapy 6.
  • One study found that tongue conservation treatment with induction chemotherapy, surgery, and risk-adapted adjuvant therapy was feasible for patients with oral tongue squamous cell carcinoma who were good responders to induction chemotherapy 6.

Patient Outcomes

  • Patient outcomes for tongue cancer treatment vary depending on the stage and location of the cancer, as well as the treatment used.
  • Studies have shown that patients with base of tongue cancer who receive concurrent radiation therapy and targeted cisplatin chemotherapy (RADPLAT) have excellent survival rates and organ function 2.
  • Another study found that patients with stage III and IV base of tongue cancer who received paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy had a high complete response rate and excellent survival rates 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.